CROWN-I Study of Molecular and Genetic Features in Alzheimers Disease, Mild Cognitive Impairment, and Normal Aging

What this Trial Is About

Researchers are studying Alzheimers disease AD and mild cognitive impairment MCI to better understand molecular and genetic differences among patient subtypes and how these differences relate to disease progression. This observational study also includes cognitively normal participants as controls. The goal is to gather detailed molecular and clinical information that could inform future therapies and clinical strategies. Participants will provide samples such as olfactory neuron cells and blood at several visits over the study period. They will also complete cognitive and clinical assessments both in person and virtually. The study tracks changes over time, aiming to capture molecular signatures that distinguish different participant groups. During the study, participants will attend baseline and follow-up visits for up to 18 months. Assessments include cognitive tests like the Clinical Dementia Rating Sum of Boxes CDR-SB, Mini-Mental State Examination MMSE, and Rey Auditory Verbal Learning Test RAVLT. Researchers will analyze changes in molecular profiles from olfactory neurons and blood, monitor progression of cognitive symptoms, and collect detailed medical histories. Participants will be observed for safety and adherence throughout the study.

Crownlands Observing Progression With Neurons Study